DBV Technologies to Participate in Upcoming Investor Conferences

Rhea-AI Summary

DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical firm, announced participation in two virtual investor conferences in May 2021. Dr. Pharis Mohideen and CFO Sebastien Robitaille will represent the company at the Kempen Life Sciences Conference on May 5, while CEO Daniel Tassé and Robitaille will attend the Societe Generale Nice Conference on May 27. DBV is focused on developing Viaskin™, a novel technology platform for immunotherapy aimed at treating food allergies through epicutaneous delivery.

Montrouge, France, April 29, 2021

DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following upcoming virtual investor conferences in May 2021.

Kempen Life Sciences Conference, May 5, 2021
Dr. Pharis Mohideen, Chief Medical Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.

Societe Generale Nice Conference, May 27, 2021
Daniel Tassé, Chief Executive Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Attachment

• PDF Version

FAQ

What conferences is DBV Technologies participating in May 2021?

DBV Technologies will participate in the Kempen Life Sciences Conference on May 5 and the Societe Generale Nice Conference on May 27, 2021.

Who is representing DBV Technologies at the Kempen Life Sciences Conference?

Dr. Pharis Mohideen, Chief Medical Officer, and Sebastien Robitaille, Chief Financial Officer, will represent DBV Technologies at the Kempen Life Sciences Conference.

What is the focus of DBV Technologies' Viaskin™ technology?

Viaskin™ is an investigational platform for immunotherapy aimed at treating food allergies through epicutaneous delivery.

Where is DBV Technologies headquartered?

DBV Technologies is headquartered in Montrouge, France, with North American operations in Summit, NJ.

What is the stock symbol for DBV Technologies?

The stock symbol for DBV Technologies is DBVT on the Nasdaq Stock Market and DBV on Euronext.